04 Dec

HealthBeacon welcomes Boston Irish Business Association to its Dublin HQ

Silicon Republic: Kelly Earley is a journalist with Siliconrepublic.com

HealthBeacon’s new CEO for North America, Laura Hamilton, hopes to strengthen links between businesses in Ireland and Boston.

This week, medtech firm HealthBeacon, which is headquartered between Dublin and Boston, welcomed the Boston Irish Business Association (BIBA) and its 2019 trade mission delegation to the company’s Irish headquarters.

The trade mission was led by Cork-born Laura Hamilton, who is the newly appointed CEO for HealthBeacon’s North American operations. As well as leading the company’s US arm, Hamilton is also the current BIBA president.

The Boston delegation’s visit to HealthBeacon was one stop on a journey through Belfast, Donegal, Derry, Dublin and Cork. The purpose of the trade mission is to look at the potential for transatlantic collaboration. It is hoped that the mission will bring together high-profile US business leaders to grow and strengthen business relationships throughout Ireland.

The BIBA delegates were given a site tour and product overview of HealthBeacon’s Dublin facility, which was led by the company’s co-founder Jim Joyce, who is also a Boston native.

HealthBeacon is developing smart tools for managing medication. Its Smart Sharp Bin aims to make it easier for patients using injectable medicines to stay on track with their treatment schedule and allow carers to track a patient’s progress.

Poised for US growth

Hamilton, who was born in Cork but grew up in Boston, played an instrumental role in bringing BIBA to Ireland for the first time in 10 years.

“After years of planning and discussion, I am thrilled to lead the BIBA trade mission to Ireland, especially as the incoming HealthBeacon CEO for the North American division,” Hamilton said.

“I have been closely connected to HealthBeacon for many years and admire the leadership, the team they’ve developed and early success achieved across Europe.

“The business is poised for tremendous growth in North America through creating value in the healthcare ecosystem with a unique world leading technology, tracking patient adherence with injectable medications for chronic disease.”

To date, HealthBeacon’s platform has been used to track more than 300,000 injections in patient’s homes. The Smart Sharp Bin has been launched in 13 countries.

Joyce said: “I first got to know Laura over four years ago in her time as director of business development at the Massachusetts Biotechnology Council (MassBio) and as BIBA president. HealthBeacon are delighted to appoint a talented business innovator and welcome this important trade mission to our Irish headquarters.”

Since it was founded in 2013, HealthBeacon has raised $15m in funding. Earlier this year, the company announced plans to expand into Asia and the US.

HealthBeacon welcomes Boston Irish Business Association to its Dublin HQ

21 Nov

Laura Hamilton to become CEO of North America for HealthBeacon

Laura Hamilton to become CEO of North America for HealthBeacon

Nov 21ST 2019, Dublin, Ireland and Boston Headquartered, HealthBeacon, a leading global medical adherence technology provider whose mission is to “build smart tools for managing medications” will be establishing a dedicated North American division to drive the development of its business and technology platform across the USA and Canada.

It’s FDA cleared “best in class” medical adherence tool for tracking injectable medications has already been launched in 13 countries and has tracked over 300,000 Injections in patient’s homes, globally. At the recent Connected Health Conference in Boston, HealthBeacon published peer-reviewed evidence demonstrating the ability for patients to successfully adopt their technology as a result of patient-centered design.  The platform has been designed to improve long term adherence to medication regimes and provide critical health data back to clinicians.

HealthBeacon’s Boston office can be described as just “Off Broadway” located above the CVS pharmacy on West Broadway in South Boston. Their Boston office has full business development, technical operations and customer care capabilities which are integrated into clinical systems, research organisations, and pharmaceutical patient support programs.

In her role as CEO of North America, Laura will be responsible for developing both the market and the HealthBeacon organisation across this important region and will report into Co-Founder and CEO, Jim Joyce.

I first got to know Laura over 4 years ago in her time as Director of Business Development of the Massachusetts Biotechnology Council (MassBio) and in her capacity as President of BIBA (Boston Irish Business Association). She is a high energy, talented leader and we couldn’t be more excited to welcome her into the company at such an exciting time.Jim Joyce, CEO and Co-Founder, HealthBeacon.

Upon joining the company this week, Laura stated, “I am delighted to be joining HealthBeacon as CEO of North America, based at the US Headquarters in Boston, MA. I’ve been closely connected to the company for many years and truly admire the leadership, the team they’ve developed, as well as the early successes they’ve achieved across Europe. The business is poised for tremendous growth in North America and is creating value in the healthcare ecosystem with their world leading technology, which tracks patient adherence to injectable medications for chronic disease. I’m so looking forward to getting started and joining the team of one of Ireland’s most innovative start-ups.

MassBio President & CEO Robert Coughlin added, “The convergence between digital health and the life sciences is creating incredible opportunities to transform patient care. With Laura joining the team, I am excited to watch HealthBeacon grow in Massachusetts and beyond as it advances solutions to improve health outcomes.

Laura most recently served as Executive Vice President, US Operations for RxCelerate, an outsourced drug discovery and drug development platform company based in Cambridge UK. Prior to that role, Laura was Director of Business Development at MassBio. She is a proud three-time graduate of Northeastern University in Boston with a BSBA in Finance, Masters Degree in Innovation (MSc) and Master of Business Administration (MBA). A native of Cork, Ireland, Laura is currently the President of the Boston Irish Business Association (BIBA) and also serves on the Board of Directors at the American Heart Association – Metro Boston.

Laura Hamilton HealthBeacon’s CEO of North America

HealthBeacon Boston Office

13 Nov

The Impact of Connected Devices on Medication Adherence

Sean Glynn, M.S., is the Director of HEOR and Strategic Initiatives for HealthBeacon in North America

Zara Fullerton Kinsella, Medical Doctor, is the Medical Science Liaison for HealthBeacon

A physician recently described an interaction where a patient was ending a course of therapy due to a poor response to treatment. The patient asked, “What should I do with the leftover medication I have at home?”  The doctor replied, “I thought you said you were taking all of your medication.  Why do you have leftover medication?”

This is not an isolated event. One out of every two patients fail to take their medication as directed and have stopped treatment within a twelve-month period. For those of us familiar with the medication non-adherence problem, this is not surprising. Hippocrates was known to have said, “Keep a watch also on the faults of the patients, which often make them lie about the taking of things prescribed.”

Our generation is asking for connected devices to be a positive force for change in every aspect of health support, and adherence is no exception. The health and technology industries are making multi-billion dollar investments so that connected devices can fundamentally transform the delivery of healthcare. Technology offers a wide variety of solutions from smart packaging to robotic dispensers, the Internet of Things offers connected devices that monitor when medicine is unpackaged and even when a used needle is disposed into a smart sharps container. Mobile technology can remind and reward patients to help them stay on track with their medication and software platforms convey, synthesize and prioritize cohort data for clinicians. In addition, artificial intelligence can offer insights into big data and predict required interventions before a patient becomes symptomatic.

Getting health data from patients has challenged the industry to innovate. Our approach at HealthBeacon has been to use the Internet of Things to passively track what the patient is already doing, in this case, disposing of a used pen or syringe into a sharps container. By capturing this behavior and relaying the information to patients, caregivers and physicians, a key data point is created. This collection of data on a real-time basis can serve to increase patient engagement, lead to more informed clinical decision making and ultimately enable the early identification of patients who may benefit from interventions that focus on improving adherence.

If this patient had been in possession of an adherence monitoring device, their story would have been very different. Any missed doses of medication would have immediately been identified and shared with their healthcare provider or caregiver, enabling them to receive the support they need to maximize outcomes from their treatment.

Connected devices have the potential to identify and support those patients who need the most help with managing their medication. Given the magnitude of this group, these technologies have a transformative role to play in improving patient care and enriching the relationship between physicians, patients and caregivers.

Media enquiries: Mary Principe  | Email: events@healthbeacon.com

13 Nov

HealthBeacon appoints Sean Glynn as first Director of HEOR, and Dr. Zara Fullerton Kinsella as first Medical Science Liaison

HealthBeacon appoints first Director of HEOR and hires first Medical Science Liaison.

(Dublin, Ireland; Boston, MA, – November 13th, 2019) Leading medication adherence technology company, HealthBeacon has announced the appointments of Sean Glynn as Director of Health Economics and Outcomes Research, and Dr. Zara Fullerton Kinsella as Medical Science Liaison.

Sean Glynn, Director of HEOR, joined the HealthBeacon team three years ago with the critical role of launching HealthBeacon’s operations in the US. Sean’s background in behavioral sciences and his deep understanding of the medication adherence issue will be instrumental in furthering HealthBeacon’s mission to improve patient outcomes by delivering new adherence solutions to patient’s who self-administer injectable medications in their homes. Sean is based out of HealthBeacon’s Boston office.

Dr. Zara Fullerton Kinsella has joined the HealthBeacon team as a Medical Science Liaison, to facilitate clinical research and assist with Regulatory Affairs. Zara is a medical doctor with an undergraduate degree in Business and Economics at Trinity College. Her keen interest in healthcare led her to study Graduate Entry Medicine at University College Cork. As a junior doctor, she worked in a variety of medical specialties. Zara is based out of HealthBeacon’s office in Dublin, Ireland.

These appointments will further HealthBeacon’s commitment to evidence-based decision making and program design. “We are excited to expand our team and add these critical capabilities with Sean being promoted to Director of HEOR and Dr. Zara joining the team as our Medical Science Liaison” said Jim Joyce, CEO of HealthBeacon, “these roles will bring through our latest studies, data projects and provide important medical insights into product development.”

About HealthBeacon

HealthBeacon is a medication adherence technology company which develops smart tools for managing medication at home. HealthBeacon’s FDA cleared smart sharps bin tracks patient injection history, provides personalized interactive reminders and safely stores used injectables. With the intervention of HealthBeacon’s Smart Sharps Technology, patients’ persistence and adherence increased by 25-30% within twelve months of initiating therapy. The HealthBeacon integrated model connects a patient’s routine and the prescribing clinician’s workflow. This technology has been adopted across thirteen countries with >300,000 injections tracked since launch in 2014, with a patient acceptance rate of
80-90%.

 

HealthBeacon’s Medical Science Liaison Dr. Zara Fullerton Kinsella

HealthBeacon’s HEOR Sean Glynn

Media Enquiries: Mary Principe  | Email: events@healthbeacon.com

18 Sep

HealthBeacon reveals strategic investors in Asia and the US, SGInnovate and Manatt Health

HealthBeacon, a medication adherence technology company based in Dublin receives investment from international strategic partners, SGInnovate and Manatt. 

(Dublin, Ireland; Singapore, – September 18th, 2019) Dublin and Boston based digital health company, HealthBeacon announces that SGInnovate (Singapore) and Manatt (USA) have become strategic investors in HealthBeacon as part of the final completion of the Series A fundraising announced in January. The total Series A fundraising was $12M bringing the total funding into the company of $15M.

Jim Joyce, Co-Founder, and CEO of HealthBeacon said, “We are delighted to have SGInnovate and Manatt on board as investors and strategic partners will assist us significantly as we bring our medical adherence technology to patients in the Asian and USA markets.”

HealthBeacon continues its expansion plan into the Asian Market. Hsien-Hui Tong, SGInnovate’s Head of Venture Investing said, “Medical non-adherence places a significant burden on healthcare systems. HealthBeacon’s use of Smart Tools to tackle this global challenge resonates well with SGInnovate’s belief in investing in best-in-class Deep Tech tackling difficult problems faced around the world. The team has shown a proven track record in improving care for patients with chronic medical conditions in Europe, the US, and Canada. SGInnovate is proud to join in as a strategic investor to help with the company’s expansion into Asia. This also marks our first healthcare investment together with Enterprise Ireland. We look forward to supporting more promising Deep Tech startups globally.”

Hsien-Hui Tong of SGInnovate. Image: SGInnovate

Lisa Suennen, Leader of Manatt said, “HealthBeacon has a proven team that is tackling a challenging and unaddressed problem in a new way. Their solution is one that both helps patients directly and improves caregivers ability to help them manage difficult conditions. We are excited to support the company and watch it grow.”

Manatt leader Lisa Suennen. Image: Manatt

The addressable market for injectable medications has reached nearly $50 billion. As of today, HealthBeacon operates in 13 markets and has tracked more than 300,000 home-based injections making it one of the largest global deployments of a medical adherence device. Today HealthBeacon employs over 40 people and plans to continue its growth over the next 18 months.

The smart sharps bin system by HealthBeacon has made it easier for patients, using injectable medications, to stay on track with their treatment schedule. This has resulted in improved patient medication adherence and driving patient care.

About SGInnovate:

SGInnovate is a private limited company wholly owned by the Singapore Government. With the support of our partners and co-investors, we back deeply technical founders through equity-based investments, access to talent, and support in building customer traction. Our efforts are prioritised around transformational technologies such as Artificial Intelligence, Quantum Tech, and MedTech, which represent impactful and scalable answers to global challenges.

About Manatt:

Manatt is an integrated professional services firm that provides strategic consulting and legal support to large and small companies.  Manatt has transformed from one of the top law firms to an industry-leading, integrated professional services firm that combines its legal capabilities with deep strategic, analytics and public policy capabilities through Manatt Health and its digital and technology businesses. Manatt Health’s interdisciplinary teams are known for engaging in leading-edge thought leadership, often working with the major healthcare foundations to develop new thinking on complex healthcare issues.

Media enquiries: Mary Principe  | Email: events@healthbeacon.com

22 Jul

U.S. Growth Hormone Adherence Patient Survey Results

Study finds that patients on growth hormone medications have difficulty adhering to their medication schedule

HealthBeacon and The MAGIC Foundation announce discoveries from a patient survey

(Boston,MA; July 16th, 2019) HealthBeacon, a medication adherence technology company, and The MAGIC Foundation, the world’s leading advocacy and information group for human growth disorders, have carried out a survey which highlights the adherence issues for patients on growth hormone medication.

Poor adherence to treatment of chronic diseases is a worldwide problem and adherence to long-term therapy for chronic illnesses in developed countries is averaging 50%. The survey highlighted a trend towards poor adherence over duration of treatment with an important drop after the first year. Across all demographics surveyed, the top reason for the patient missing their medication was due to “being too busy and forgetting”.

HealthBeacon’s Director of Operations for North America, Sean Glynn said, “It was interesting to note that one-in-five patients are self-reporting suboptimal adherence levels, highlighting the need for smart tools and support to help stay on track with treatment.” Smart Tools such as the HealthBeacon smart sharps bin system has made it easier for patients, using injectable medications, to maintain their treatment schedule and this has resulted in improved persistence to treatment by 20-30% within the first year.

“This is an important look into the challenges associated with long-term treatment for chronic conditions such as growth disorders,” commented Dianne Kremidas, Executive Director at The MAGIC Foundation. “We are delighted to share these results with patients, physicians and pharmaceutical companies to bring light to this critical issue.”

The MAGIC Foundation is the global leader in endocrine health, advocacy, education, and support. HealthBeacon believes that engaging with the world’s leading advocacy groups will provide a strong network and patient engagement program to improve medication adherence.

About HealthBeacon

HealthBeacon is a medication adherence technology company which develops smart tools for managing medication. The HealthBeacon is a smart sharps bin for patients who self-inject medications at home. It is digitally connected and programmed with a patient’s personal medication schedule and uses customized reminders to help them start and stay on track with medication. The technology has been on the market since 2013 and has tracked > 270,000 injections and is now available in the US Market. To learn more, email events@healthbeacon.com.

About The MAGIC Foundation

The MAGIC Foundation was incorporated in the state of Illinois and received 501(C)3 non-profit status October 29, 1989. Since its inception, the Foundation has grown to include support services for adults who were also impacted by these disorders.

Media enquiries: Mary Principe  | Email: events@healthbeacon.com

14 Nov

HealthBeacon signs agreement with Canada’s leading patient support provider, Innomar Strategies

HealthBeacon, partners with Innomar Strategies, to bring its smart sharps bin offering to Canada.

(DUBLIN, IE., TORONTO, ON. –November 14th, 2018) HealthBeacon announced today their partnership with Innomar Strategies to provide the HealthBeacon smart sharps bin and digital therapeutic platform to Canadian patients across the country.

HealthBeacon is a Dublin headquartered, digital therapeutic company that produces a smart sharps bin to track and drive medication adherence. Following their recent FDA clearance in the US, HealthBeacon has begun investing resources in the North American markets of the United States and Canada. Innomar Strategies, a part of AmerisourceBergen, is the leading patient support provider in the Canadian specialty biopharmaceutical market, helping patients navigate the complicated Canadian healthcare system, and providing support for their injections and infusions.

“We have seen great patient engagement with the HealthBeacon tool in Ireland. It has been instrumental in aiding us in identifying patients that need assistance, and helping drive adherence to their medication. I’m delighted to see they are making HealthBeacon available in Canada.” – Dr. Trevor Duffy, Rheumatologist

HealthBeacon began operations in Canada with the opening of their Montreal office in December 2016. HealthBeacon CEO, Jim Joyce commented, The Canadian market is a large market, both geographically and in terms of patients who could benefit from our technology. The signing of this partnership is a major milestone in making our technology accessible to the Canadian market.

As an industry leader, Innomar deeply understands the patient journey.  A core focus is delivering best-in-class care and education through patient services to monitor adherence and ensure optimal outcomes.

“We look forward to partnering with HealthBeacon as they move into the Canadian market.  Our focus is on patient care, and having a tool to track and facilitate medication adherence brings value to patient care across Canada,” says Amar Pabla, Vice President Nursing, Clinics and Pharmacovigilance.

“HealthBeacon are a fantastic example of Irish innovation. This partnership is testimony to the deepening links between Irish and Canadian healthcare. As the government agency driving the growth of Irish businesses internationally, we at Enterprise Ireland look forward to seeing HealthBeacon support Innomar Strategies in its mission to advance patient support across Canada.” – Neil Cooney, Country Manager Canada, Enterprise Ireland

About HealthBeacon

HealthBeacon is a Digital Therapeutics company that develops smart tools for managing medication. The HealthBeacon is a smart sharps bin for patients who self-inject medications at home. It is digitally connected and programmed with a patient’s personal medication schedule, and uses customized reminders to help them start and stay on track with medication. The company is headquartered in Dublin, Ireland and has offices in the US and in Canada. Learn more at www.healthbeacon.com

About Innomar Strategies

Innomar Strategies, a part of AmerisourceBergen, is the leading patient support provider in the Canadian specialty biopharmaceutical market. We deliver end-to-end commercialization solutions to improve product access, increase supply chain efficiency and enhance patient care. Strategic consulting, patient support programs, nursing and clinical services, and specialty pharmacy and logistics are just a few of our key areas of specialization. We partner closely with manufacturers, healthcare providers, pharmacies and payers to ensure patients have consistent and reliable access to specialty medication. With our integrated approach and commitment tobest-in-class care, Innomar Strategies helps navigate the patient journey to optimize health outcomes. Visit us at www.innomarstrategies.com.

25 Oct

HealthBeacon Sponsors Ireland’s Cancer Fund for Children

HealthBeacon will be supporting the Cancer Fund for Children as the “Speakeasy” Sponsor at this years’ Gala Ball. The Gala Ball is part of a 5-year program that aims to raise €1m for the Cancer Fund for Children. They are in large part supported by Ireland’s Digital Economy with its inaugural 2017 Gala Ball raising more than €137,000. The goal is to build a brand new therapeutic centre for children diagnosed with cancer, and their families, in Ireland.

Cancer Fund for Children has been supporting families for over forty years. They offer practical, emotional and financial help and also include stress-relieving, nurturing breaks at their therapeutic centre Daisy Lodge in County Down. Unfortunately, the overwhelming need has the centre operating at full capacity and created a long wait list for families.

This fundraising program will bring Daisy Lodge Connacht to the west of Ireland. This worthy project is supported by prominent Irish citizens such as professional golfer Rory McIlroy and will be attended by over 300 people including Paul Harrington, Bobby Kerr, Holly Carpenter and Eddie Irvine.

“HealthBeacon is delighted to be sponsoring this great event and worthy cause. The Cancer Fund for Children has ambitious plans for their new therapeutic centre in Mayo. This site will be entirely dedicated to support children and their families that have been diagnosed with cancer.” Jim Joyce, CEO HealthBeacon

For more information on the project, please see https://cancerfundforchildren.com/event/great-gatsby-gala-ball/

24 Oct

HealthBeacon attends Johnson & Johnson, JLABS CEO Summit

HealthBeacon are delighted to attend the 2nd annual JLABs CEO Summit in sunny La Jolla, San Diego. 

The event has gathered partners of Johnson & Johnson’s, JLABs group for two days of networking and information exchange as well as talks and panel discussions with industry leaders. 

HealthBeacon has been part of the global JLABs network after being chosen as the winner of the Johnson & Johnson Innovation, JLABS and Janssen Supply Chain Group, LLC (JSC) Patient Adherence QuickFire Challenge earlier this year.

Since winning the QuickFire Challenge, HealthBeacon has achieved FDA clearance for it’s smart sharps bin and launched in an additional four markets including the U.S. so there is a lot to catch up on with old friends and new at the event. 

This coupled with the growth of our product portfolio and data analytics platform offers a clear point of intersection within the JLABs ecosystem.

Having completed day one of the event which was focussed on JPAL & Investor Partnering we are excited to partake in the CEO Summit main program which began tonight featuring talks from J&J executives, JLABS CEOs, investors and industry leaders, and continues on Wednesday 24th.

 

22 Nov

HealthBeacon Announces New Round of Investment Funding

Dublin based med tech company, HealthBeacon, this morning announced the company is embarking on a new round of investment funding seeking €5m before 2018 year end.

The announcement was made at “Investing in Digital Health” a major private investor event hosted by the digital health company earlier this morning. The breakfast event in Royal College of Physicians gathered authorities from medical tech, med entrepreneurs, investment trailblazers and medical experts from all over Ireland.

A keynote presentation regarding “Emerging Trends and impact of Digital and Connected Heath” was delivered by Chandana Fitzgerald, Medical Lead, HealthXL.

HealthBeacon designed “Investing in Digital Health” to bring together some of the most forward thinking technology and healthcare minds to discuss the growth and opportunity for investing in digital health around the panel discussion on ‘Emerging trends and impact of connected health’ – from a Global Perspective.

‘We believe that investing in Digital Health not only substantially improves patient outcomes and delivers a return for national health systems, it creates new employment and investor returns also. Ireland is building on its reputation in the Life Sciences and Medtech arenas by now producing quality Digital Health companies such as Health Beacon that are capable of competing Internationally. We see this as a major area of interest going forward.’ Liam Kiely of Cantor Fitzgerald

Event panellists, led by Mike Ryan, Founding Director of Irrus Investments as panel moderator included Jim Joyce CEO HealthBeacon, Conor Hanley, CEO, Fire1 and Rosanne Longmore, CEO Coroflo who were recently awarded €250,000 from Enterprise Ireland and successfully raised €900,000 within its first six months.

We are excited to announce HealthBeacon’s next investment phase, as we continue to move towards global connection of healthcare through assisting in clever patient medication management and revolutionizing medication adherence.   Our technology provides powerful insights for medics by providing real world patient data.  Jim Joyce, CEO, HealthBeacon

To date HealthBeacon has raised over €3m with current investors including Elkstone Partners and Oyster Capital.

HealthBeacon were recently awarded ‘Pharma Project of the Year – Large’ at the Pharma Industry Awards 2017.  HealthBeacon announced the creation of 20 new jobs for the Dublin based digital health earlier this year.

The “Smart Sharps System” helps patients adhere to their medication schedule. Current estimated costs to manage medication non-adherence is estimated to be $290 billion in the US market alone. The use of HealthBeacon smart technology aims to make a dramatic impact to cost savings within the healthcare industry. The expansion of the platform will provide access to the technology globally in Europe, North America, South America and the Middle East.